In vitro inhibition of human UGT isoforms by ritonavir and cobicistat

References

• Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, et al. (2005). Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther 78:664–74
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ, Ameer B, et al. (1985). Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. J Pharmacol Exp Ther 234:345–9
   PubMed Web of Science ®Google Scholar
• Bertelsen KM, Venkatakrishnan K, von Moltke LL, et al. (2003). Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 31:289–93
   PubMed Web of Science ®Google Scholar
• Bock KW, Forster A, Gschaidmeier H, et al. (1993). Paracetamol glucuronidation by recombinant rat and human phenol UDP-glucuronosyltransferases. Biochem Pharmacol 45:1809–14
   PubMed Web of Science ®Google Scholar
• Court MH. (2010). Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 42:209–24
   PubMed Web of Science ®Google Scholar
• Eichbaum C, Cortese M, Blank A, et al. (2013). Concentration effect relationship of CYP3A inhibition by ritonavir in humans. Eur J Clin Pharmacol 69:1795–800
   PubMed Web of Science ®Google Scholar
• Gallant JE, Koenig E, Andrade-Villanueva J, et al. (2013). Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis 208:32–9
   PubMed Web of Science ®Google Scholar
• Gatti G, Di Biagio A, Casazza R, et al. (1999). The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS 13:2083–9
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ. (2014). Antiretroviral boosting by cobicistat, a structural analog of ritonavir. Clin Pharmacol Drug Dev 3:335–7
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ. (2016). Evidence-based choice of ritonavir as index CYP3A inhibitor in drug-drug interaction studies. J Clin Pharmacol 56:152–6
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ. (2017). Mechanisms and consequences of drug-drug interactions. Clin Pharmacol Drug Dev 6:118–24
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Harmatz JS. (2015). Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies. Br J Clin Pharmacol 80:342–50
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL, Harmatz JS, et al. (2000a). Alprazolam–ritonavir interaction: implications for product labeling. Clin Pharmacol Ther 67:335–41
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL, Harmatz JS, et al. (2000b). Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 24:129–36
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL, Harmatz JS, et al. (2003). Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol 43:414–22
   PubMed Web of Science ®Google Scholar
• Hsu A, Granneman GR, Bertz RJ. (1998). Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35:275–91
   PubMed Web of Science ®Google Scholar
• Kuehl GE, Lampe JW, Potter JD, et al. (2005). Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos 33:1027–35
   PubMed Web of Science ®Google Scholar
• Larson KB, Wang K, Delille C, et al. (2014). Pharmacokinetic enhancers in HIV therapeutics. Clin Pharmacokinet 53:865–72
   PubMed Web of Science ®Google Scholar
• Luukkanen L, Mikkola J, Forsman T, et al. (2001). Glucuronidation of 1-hydroxypyrene by human liver microsomes and human UDP-glucuronosyltransferases UGT1A6, UGT1A7, and UGT1A9: development of a high-sensitivity glucuronidation assay for human tissue. Drug Metab Dispos 29:1096–101
   PubMed Web of Science ®Google Scholar
• Mano Y, Usui T, Kamimura H. (2004). Effects of beta-estradiol and propofol on the 4-methylumbelliferone glucuronidation in recombinant human UGT isozymes 1A1, 1A8 and 1A9. Biopharm Drug Dispos 25:339–44
   PubMed Web of Science ®Google Scholar
• Mathias AA, German P, Murray BP, et al. (2010). Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 87:322–9
   PubMed Web of Science ®Google Scholar
• Mutlib AE, Goosen TC, Bauman JN, et al. (2006). Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity. Chem Res Toxicol 19:701–9
   PubMed Web of Science ®Google Scholar
• Perloff MD, Störmer E, von Moltke LL, et al. (2003). Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm Res 20:1177–83
   PubMed Web of Science ®Google Scholar
• Renjifo B, van Wyk J, Salem AH, et al. (2015). Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat. AIDS Rev 17:37–46
   PubMed Web of Science ®Google Scholar
• Rowland A, Miners JO, Mackenzie PI. (2013). The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol 45:1121–32
   PubMed Web of Science ®Google Scholar
• Rowland Yeo K, Walsky RL, Jamei M, et al. (2011). Prediction of time-dependent CYP3A4 drug–drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. Eur J Pharm Sci 43:160–73
   PubMed Web of Science ®Google Scholar
• Shah BM, Schafer JJ, Priano J, et al. (2013). Cobicistat: a new boost for the treatment of human immunodeficiency virus infection. Pharmacotherapy 33:1107–16
   PubMed Web of Science ®Google Scholar
• Turner KC, Brouwer KL. (1997). In vitro mechanisms of probenecid-associated alterations in acetaminophen glucuronide hepatic disposition. Drug Metab Dispos 25:1017–21
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Obach RS, Rostami-Hodjegan A. (2007). Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug–drug interaction risk assessment. Xenobiotica 37:1225–56
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Grassi JM, et al. (1998). Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 38:106–11
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Harmatz JS, et al. (1993a). Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 47:268–76
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Manis M, Harmatz JS, et al. (1993b). Inhibition of acetaminophen and lorazepam glucuronidation in vitro by probenecid. Biopharm Drug Dispos 14:119–30
   PubMed Web of Science ®Google Scholar
• Xu L, Liu H, Murray BP, et al. (2010). Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett 1:209–13
   PubMed Web of Science ®Google Scholar
• Yeh KC, Deutsch PJ, Haddix H, et al. (1998). Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother 42:332–8
   PubMed Web of Science ®Google Scholar
• Yung-Chi C, Prusoff WH. (1973). Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–108
   PubMed Web of Science ®Google Scholar